145 related articles for article (PubMed ID: 38069911)
1. MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.
Blewett T; Rhoades J; Liu R; Xiong K; Sridhar S; Crnjac A; Cheng J; Lawless AR; Frederick DT; Flaherty KT; Makrigiorgos GM; Adalsteinsson VA
Clin Chem; 2024 Feb; 70(2):434-443. PubMed ID: 38069911
[TBL] [Abstract][Full Text] [Related]
2. Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth.
Gydush G; Nguyen E; Bae JH; Blewett T; Rhoades J; Reed SC; Shea D; Xiong K; Liu R; Yu F; Leong KW; Choudhury AD; Stover DG; Tolaney SM; Krop IE; Christopher Love J; Parsons HA; Mike Makrigiorgos G; Golub TR; Adalsteinsson VA
Nat Biomed Eng; 2022 Mar; 6(3):257-266. PubMed ID: 35301450
[TBL] [Abstract][Full Text] [Related]
3. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
4. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.
Li S; Zeng W; Ni X; Zhou Y; Stackpole ML; Noor ZS; Yuan Z; Neal A; Memarzadeh S; Garon EB; Dubinett SM; Li W; Zhou XJ
Clin Cancer Res; 2022 May; 28(9):1841-1853. PubMed ID: 35149536
[TBL] [Abstract][Full Text] [Related]
5. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
[TBL] [Abstract][Full Text] [Related]
6. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.
Parsons HA; Rhoades J; Reed SC; Gydush G; Ram P; Exman P; Xiong K; Lo CC; Li T; Fleharty M; Kirkner GJ; Rotem D; Cohen O; Yu F; Fitarelli-Kiehl M; Leong KW; Hughes ME; Rosenberg SM; Collins LC; Miller KD; Blumenstiel B; Trippa L; Cibulskis C; Neuberg DS; DeFelice M; Freeman SS; Lennon NJ; Wagle N; Ha G; Stover DG; Choudhury AD; Getz G; Winer EP; Meyerson M; Lin NU; Krop I; Love JC; Makrigiorgos GM; Partridge AH; Mayer EL; Golub TR; Adalsteinsson VA
Clin Cancer Res; 2020 Jun; 26(11):2556-2564. PubMed ID: 32170028
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
8. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
[TBL] [Abstract][Full Text] [Related]
9. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.
Pasca S; Guo MZ; Wang S; Stokvis K; Shedeck A; Pallavajjala A; Shams C; Pallavajjala R; DeZern AE; Varadhan R; Gocke CD; Jones RJ; Gondek LP
Blood Adv; 2023 Aug; 7(16):4660-4670. PubMed ID: 37276081
[TBL] [Abstract][Full Text] [Related]
11. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
[TBL] [Abstract][Full Text] [Related]
12. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
[TBL] [Abstract][Full Text] [Related]
13. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
15. Calibration-free NGS quantitation of mutations below 0.01% VAF.
Dai P; Wu LR; Chen SX; Wang MX; Cheng LY; Zhang JX; Hao P; Yao W; Zarka J; Issa GC; Kwong L; Zhang DY
Nat Commun; 2021 Oct; 12(1):6123. PubMed ID: 34675197
[TBL] [Abstract][Full Text] [Related]
16. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay.
Qi Z; Li Y; Wang Z; Tan X; Zhou Y; Li Z; Zhao W; Zheng X; Yao J; Li F; Wang W; Wang Z; Pang F; Wang G; Gu W
Cancer Med; 2023 Aug; 12(16):16687-16696. PubMed ID: 37602656
[TBL] [Abstract][Full Text] [Related]
18. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
19. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.
Liu W; Li Y; Tang Y; Song Q; Wang J; Li N; Chen S; Shi J; Wang S; Li Y; Jiao Y; Zeng Y; Jin J
EBioMedicine; 2022 Apr; 78():103945. PubMed ID: 35306340
[TBL] [Abstract][Full Text] [Related]
20. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
